Mutations in the oncoprotein KRAS occur in about 25% of cancer cases and are associated with poor prognosis of the disease. Therefore, scientists believe that blocking KRAS signaling is a potential anti-cancer pathway. However, previous decades of research have shown that this protein may be a “non-medicinal” target because… Continue Reading Nature: KRAS drugs enter the “outbreak period”, 5 products carry out human trials